Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 1.00 |
| ▸ | LCK | P06239 | 2/20 | 0.97 |
| ▸ | FBP1 | P09467 | 3/20 | 0.78 |
| ▸ | KDR | P35968 | 6/20 | 0.75 |
| ▸ | RET | P07949 | 5/20 | 0.75 |
| ▸ | SRC | P12931 | 3/20 | 0.75 |
| ▸ | EPHB2 | P29323 | 2/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.73 |
| ▸ | ABL1 | P00519 | 2/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.73 |
| ▸ | MAPT | P10636 | 2/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.73 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.73 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.73 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.73 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.73 |
| ▸ | FLT1 | P17948 | 1/20 | 0.73 |
| ▸ | CDK2 | P24941 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5475745 | 0.99 | EGFR (1.00) | EGFRLCKFBP1KDRRET | |
| SCHEMBL18158231 | 0.91 | EGFR (0.83) | EGFRLCKFBP1KDRRET | |
| SCHEMBL10101988 | 0.90 | EGFR (0.82) | EGFRLCKFBP1KDRRET | |
| SCHEMBL668572 | 0.90 | EGFR (0.81) | EGFRLCKFBP1KDRRET | |
| SCHEMBL10101915 | 0.88 | EGFR (0.78) | EGFRLCKFBP1KDRRET | |
| Hydrochloric Acid SCHEMBL668222 | 0.88 | EGFR (0.80) | EGFRLCKFBP1KDRRET | |
| Hydrochloric Acid SCHEMBL668383 | 0.88 | EGFR (0.80) | EGFRLCKFBP1KDRRET | |
| SCHEMBL7119658 | 0.88 | FBP1 (1.00) | EGFRLCKFBP1ERBB2 | |
| SCHEMBL31067733 | 0.87 | KDR (0.80) | EGFRLCKKDR | |
| SCHEMBL14551678 | 0.87 | FBP1 (0.77) | EGFRLCKFBP1KDRRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040039002-A1 | 6,7-Dimethoxyquinazolines and therapeutic use thereof | PARKER HUGHES INSTITUTE | 2004-02-26 | — | — | US | claimed |
| JP-2002540103-A | — | — | 2002-11-26 | — | — | JP | claimed |
| US-20020137757-A1 | Quinazolines and therapeutic use thereof | PARKER HUGHES INSTITUTE (US) | 2002-09-26 | — | — | US | claimed |
| US-20020111360-A1 | Quinazoline formulations and therapeutic use thereof | PARKER HUGHES INSTITUTE | 2002-08-15 | — | — | US | claimed |
| EP-1163228-A1 | QUINAZOLINES AND THERAPEUTIC USE THEREOF | Parker Hughes Institute (US) | 2001-12-19 | — | — | EP | claimed |
| EP-1162974-A1 | QUINAZOLINE FORMULATIONS AND THERAPEUTIC USE THEREOF | Parker Hughes Institute (US) | 2001-12-19 | — | — | EP | claimed |
| US-20010016588-A1 | Quinazolines and therapeutic use thereof | HUGHES INSTITUTE (US) | 2001-08-23 | — | — | US | claimed |
| US-6258820-B1 | ANTITUMOR AGENTS | PARKER HUGHES INSTITUTE | 2001-07-10 | — | — | US | claimed |
| WO-2000056338-A1 | QUINAZOLINE FORMULATIONS AND THERAPEUTIC USE THEREOF | PARKER HUGHES INSTITUTE (US) | 2000-09-28 | — | — | WO | claimed |
| WO-2000056720-A1 | QUINAZOLINES AND THERAPEUTIC USE THEREOF | PARKER HUGHES INSTITUTE (US) | 2000-09-28 | — | — | WO | claimed |
| US-8513267-B2 | 4-anilinoquinazoline derivatives with adenosine-kinase inhibitor properties | UNIVERSIDADE ESTADUAL DE CAMPINAS-UNICAMP (BR) | 2013-08-20 | — | — | US | disclosed |
| EP-1737832-B1 | 4-ANILINOQUINAZOLINE DERIVATIVES WITH ADENOSINE-KINASE INHIBITORY PROPERTIES | UNICAMP (BR) | 2011-12-14 | — | — | EP | disclosed |
| US-20070060600-A1 | 4-Anilinequinazolines with adenosine-kiase inhibitor properties | UNIVERSIDADE ESTADUAL DE CAMPINAS-UNICAMP (BR) | 2007-03-15 | — | — | US | disclosed |
| US-7038049-B2 | Haloanilino quinazolines and therapeutic use thereof | PARKER HUGHES INSTITUTE (US) | 2006-05-02 | — | — | US | disclosed |
| US-20050075353-A1 | Quinazolines and therapeutic use thereof | PARKER HUGHES INSTITUTE (US) | 2005-04-07 | — | — | US | disclosed |
| US-6258820-B1 | ANTITUMOR AGENTS | PARKER HUGHES INSTITUTE | 2001-07-10 | — | — | US | disclosed |
| WO-2000072849-A1 | NOVEL EPIDERMAL GROWTH FACTOR RECEPTOR-BINDING COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2000-12-07 | — | — | WO | disclosed |
| US-6126917-A | RADIOLABELED COMPOUND | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2000-10-03 | — | — | US | disclosed |
| WO-2000056338-A1 | QUINAZOLINE FORMULATIONS AND THERAPEUTIC USE THEREOF | PARKER HUGHES INSTITUTE (US) | 2000-09-28 | — | — | WO | disclosed |
| WO-2000056720-A1 | QUINAZOLINES AND THERAPEUTIC USE THEREOF | PARKER HUGHES INSTITUTE (US) | 2000-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075353-A1 | Quinazolines and therapeutic use thereof | HRH2, HRH4, HNMT | EGFR 1931/4885LCK 181/4885FBP1 3422/4885 |
| US-20020111360-A1 | Quinazoline formulations and therapeutic use thereof | CMA1, MAST3, MAST1 | EGFR 3336/4885LCK 525/4885FBP1 1243/4885 |
| US-20070060600-A1 | 4-Anilinequinazolines with adenosine-kiase inhibitor properties | ADK, AK1, ADORA3 | EGFR 3142/4885LCK 860/4885FBP1 2369/4885 |
| US-20020137757-A1 | Quinazolines and therapeutic use thereof | HRH2, HRH4, HNMT | EGFR 1931/4885LCK 181/4885FBP1 3422/4885 |
| US-20040039002-A1 | 6,7-Dimethoxyquinazolines and therapeutic use thereof | HRH2, HNMT, HRH4 | EGFR 1601/4885LCK 140/4885FBP1 4269/4885 |
| US-20010016588-A1 | Quinazolines and therapeutic use thereof | HRH2, HRH4, HNMT | EGFR 1931/4885LCK 181/4885FBP1 3422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.